A robotic assisted surgery for bladder lesion excision.
This is a single-center, non-randomized study to evaluate the use of the Virtuoso Endoscopy System (VES) to perform safe and effective bladder lesion excisions.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
30
This study is to evaluate the use of the Virtuoso Endoscopy System (VES), which is a robotic enhanced system, to perform safe and effective bladder lesion excisions.
Prince of Wales Hospital, Chinese University of Hong Kong
Hong Kong, Hong Kong, Hong Kong
Detrusor muscle presence in the pathologic specimen after VES procedure
Time frame: Through study completion, an average of 30 days
Adverse events
Time frame: Intraoperative
Adverse events
Time frame: Through study completion, an average of 30 days
Rate of conversion to standard cTURBT equipment
Time frame: Intraoperative
Rate of en bloc excision with VES
Time frame: Intraoperative
Complications (Clavien-Dindo)
Time frame: Intraoperative
Significant bladder perforation requiring intervention
Time frame: Intraoperative
Urethral injury
Time frame: Intraoperative
Transfusion rate
Time frame: Intraoperative
Estimated blood loss
Time frame: Intraoperative
Rate of patients where the obturator nerve complex was observed
Time frame: Intraoperative
Mortality
Time frame: Intraoperative
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
VES surgery procedural time
Time frame: Intraoperative
Presence of clear, evaluable margins in excised specimen
Time frame: Through study completion, an average of 30 days
Time of catheterization
Time frame: Through study completion, an average of 30 days
Time of hospital stay
Time frame: Through study completion, an average of 30 days
Complications (Clavien-Dindo)
Time frame: Through study completion, an average of 30 days
Significant bladder perforation requiring intervention
Time frame: Through study completion, an average of 30 days
Urethral injury
Time frame: Through study completion, an average of 30 days
30-day reoperation rate
Time frame: Through study completion, an average of 30 days
30-day hospital readmission rate
Time frame: Through study completion, an average of 30 days
30-day mortality
Time frame: Through study completion, an average of 30 days